2023-2030年全球稀有糖市场

市场概览

在预测期内（2023 年至 2030 年），全球稀有糖市场的复合年增长率为 4.2%。

单醣及其衍生物是自然界中含量极少的稀有醣类。 单醣有50多种，但大量存在的只有7种。 这些糖是 L-阿拉伯糖、D-核糖、D-木糖、D-果糖、D-甘露糖、D-半乳糖和 D-葡萄糖。 其余糖为稀有糖，其甜度约为普通糖的70%。

稀有糖被用作合成用于抗病毒和抗癌药物的核甘类似物的组成部分。 他们准备使用发酵和□促转化等有机过程来製造相同的化合物。

儘管稀有糖的天然丰度较低，但它们具有许多重要用途，例如用作抗病毒药物的成分。 此外，由于其低血糖指数，它被用作低热量甜味剂。 由于其免疫抑制特性，它也被用作抗炎剂。

市场动态

提高消费者的健康意识

摄入稀有糖有助于为註重健康的消费者带来益处。 例如，D-甘露糖单醣可减弱胰岛素反应并降低对血糖水平的影响，使其成为各种功能性食品和饮料中天然糖的更好替代品。 它还具有低血糖指数，因为它在胃肠道中被缓慢吸收，而不是像葡萄糖那样在肝臟中积累，这推动了稀有糖市场的增长。 在法国和英国，政府通过选择性征税、产品改进、预包装标籤等方式减少食糖消费，预计将促进市场扩张。 这些努力支持世卫组织 2015-2020 年欧洲食品和营养行动计划的政策建议，以营造更健康的食品环境。

遵守国际质量标准和法规

大大製约稀有糖市场增长的因素预计是通过严格的标籤和製造方法建立严格的法规和合规性来保护消费者的利益。

例如，2019 年 4 月，美国食品和药物管理局製定了用于营养和补充剂的阿洛酮糖卡路里数量指南。 根据该法律，要符合低糖或低热量产品的资格，稀有糖的製造商必须遵守严格的规定。 稀有糖市场预计将面临来自这些因素的挑战。

COVID-19 影响分析

COVID-19 分析包括 COVID 前情景、COVID 情景、COVID 后情景、价格动态（与 COVID 前情景相比，大流行期间和之后的价格变化）、供需谱（需求和供应变化由于贸易限制、封锁和后续问题）；我们还计划解释製造商的举措。

内容

第 1 章研究方法和范围

• 调查方法
• 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

• 按产品分类的片段
• 最终用户摘录
• 区域摘要

第 4 章动力学

• 影响因素
  • 司机
    • 消费者健康意识提高
  • 约束因素
    • 遵守国际质量标准和法规
  • 机会
  • 影响分析

第五章行业分析

• 波特的五力分析
• 供应链分析
• 价格分析
• 监管分析

第 6 章 COVID-19 分析

• COVID-19 分析
  • 在 COVID-19 情景之前
  • 当前的 COVID-19 情景
  • COVID-19 后或未来情景
• COVID-19 期间的价格动态
• 供需范围
• 大流行期间与市场相关的政府举措
• 製造商的战略举措
• 结论

第 7 章副产品

• D-甘露糖
• 阿洛酮糖
• L-阿拉伯糖
• L-岩藻糖
• 其他

最终用户第 8 章

• 膳食补充剂
• 化妆品和个人护理
• 医药
• 食物和饮料
• 其他

第9章按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 俄罗斯
  • 其他欧洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第10章竞争格局

• 竞争场景
• 市场分析/份额分析
• 併购分析

第11章公司简介

• 宜瑞安公司
  • 公司简介
  • 产品组合和说明
  • 财务摘要
  • 主要发展
• Nestle
• Avantor, Inc
• Tate & Lyle
• Jarrow Formulas Inc
• Shijiazhuang Huaxu Pharmaceutical Co.,Ltd
• Sanwa Starch Co., Ltd
• Zhangjiagang Sipu Biochemical Co., Ltd
• Sweet Cures Limited
• Matsutani Chemical Industry Co. Ltd

上记以外

第12章 附录

Market Overview

The global rare sugar market reached US$ XX million in 2022 and is projected to witness lucrative growth by reaching up to US$ XX million by 2030. The market is growing at a CAGR of 4.2% during the forecast period (2023-2030).

Monosaccharides and their derivatives, which are present in nature in incredibly small amounts, are rare sugars. There are over 50 different types of simple sugars, but only seven are found in significant quantities. These sugars are L-arabinose, D-ribose, D-xylose, D-fructose, D-mannose, D-galactose and D-glucose. The remaining sugar is rare and has a sweetness level of 70% of regular sugar.

The building blocks to synthesize nucleoside analogs, which are used as antiviral and anti-cancer agents, use rare sugars. They are prepared to create the same compound using organic processes like fermentation or enzyme conversion.

Despite their low natural abundance, rare sugars have many important applications, including their use as components in antiviral medications. Furthermore, because of their low glycemic index, they are used as low-calorie sweeteners. They also serve as anti-inflammatory drugs because of their immunosuppressive qualities.

Market Dynamics

Increase in health consciousness among consumers

The consumption of rare sugar helps in providing benefits for health-conscious consumers. For instance, D-Mannose monosaccharide significantly blunts insulin response and reduces the impact on blood sugar level, thus making it a better alternative as natural sugar in different functional food and beverages. It is also not stored in the liver like glucose and is absorbed more slowly in the gastrointestinal tract, thus accounting for a lower glycemic index, propelling the growth of the rare sugar market. It is anticipated that national government initiatives in France and the U.K. to reduce sugar consumption through selective taxation, product reformulations and explanatory front packaging labels will aid market expansion. These initiatives support WHO's 2015-2020 European Food and Nutrition Action Plan's policy recommendations for fostering a healthier food environment.

Adherence to international quality standards and regulations

It is anticipated that a significant restraint on the growth of the rare sugar market will come from stringent regulations and compliances designed to safeguard consumers' interests through strict labeling and manufacturing practices.

For instance, in April 2019, the U.S. Food and Drug Administration established guidelines on the number of calories in allulose for nutrition and supplementation. To qualify as low-sugar or low-calorie products under this legislation, manufacturers of rare sugar must adhere to stringent regulations. The rare sugar market is anticipated to face challenges due to such factors.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it with pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Segment Analysis

The global rare sugar market is segmented based on product, end-user and region.

Rising prevalence of urinary tract infections globally

D-Mannose segment in the rare sugar market is expected to hold a significant global market share. D-mannose is often sold as a dietary supplement for lowering the incidence of UTIs. According to research, augmented D-mannose may be a potential alternative or supplemental therapy, particularly as a preventive for recurrent UTIs. D-mannose, when discharged in urine, may prevent Escherichia coli, the principal causative bacterium of UTIs, from adhering to urothelium and causing infection. D-mannose may also prevent some types of bacteria from adhering to the urinary system walls and causing illness.

D-mannose may be safe for most individuals for up to 6 months when taken orally. Nonetheless, it has the potential to cause diarrhea and nausea.

Due to the growing demand for D-mannose treating UTIs, many manufacturers are launching new probiotic products with the respective compound. For instance, Labiana pharmaceuticals launched Precyst, a new food supplement to help the well-being of the urinary system in women, on December 16, 2020. The product comprises two natural substances with synergistic effects: D-Mannose and cranberry extract.

Furthermore, Utiva launched a new line of urinary tract health and wellness products on March 11, 2021. The new product line comprises point-of-need solutions named Utiva UTI Control 36PAC Cranberry Pills, Probiotic Power Supplements and D-Mannose Attack, some effective wellness triumvirates capable of preventing urinary tract infections.

Geographical Analysis

Asia-Pacific's growing demand for organic food and increased knowledge of healthy lifestyles and diets

According to the International Trade Centre, Japan imported the most chemically pure sugars in 2021, totaling 62,314 tons. China also imported 10,120 tons of chemically pure sugar.

Global firms are developing and entering this market area in this region through collaboration and partnership with others to expand their regional growth. For instance, GNC Holdings Inc engaged in a relationship with a Hong Kong-based Chinese e-Commerce firm in February 2019 to expand the product range of supplements such as Now D-Mannose and Source Naturals D-Mannose in China's supplement industry.

EIAs for Anhui Tiankai's nutritional supplements healthy industry project and functional and nutritional healthy food project were made public on May 17, 2021, before approval by the Government of Quanjiao County. Both projects will include allulose production lines with a total capacity of 2,500 t/a.

Baolingbao Biology Co., Ltd. stated in a Q&A forum for investors in November 2021 that the business has made full preparations for future domestic licensing of the usage of psicose.

Earlier on August 25, BLB announced the launch of a 30,000 t/a psicose (dry basis) project to prepare for the anticipated psicose market in China and meet demand from abroad markets. The project has a total investment of US$ 58.82 million (RMB380 million) and a construction span of two years; it is now in the planning stages. These development operations will generate new opportunities for regional market expansion.

Competitive Landscape

The major global players in the market include Ingredion Incorporated, Nestle, Avantor, Inc, Tate & Lyle, Jarrow Formulas Inc, Shijiazhuang Huaxu Pharmaceutical Co.,Ltd, Sanwa Starch Co., Ltd., Zhangjiagang Sipu Biochemical Co., Ltd, Sweet Cures Limited, and Matsutani Chemical Industry Co. Ltd.

Why Purchase the Report?

• To visualize the global rare sugar market segmentation based on product, end-user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of rare sugar market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global rare sugar market report would provide approximately 53 tables, 51 figures and 202 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by End-User
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increase in health consciousness among consumers
  • 4.1.2. Restraints
    • 4.1.2.1. Adherence to international quality standards and regulations
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Before COVID-19 Scenario
  • 6.1.2. Present COVID-19 Scenario
  • 6.1.3. Post COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Product

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 7.1.2. Market Attractiveness Index, By Product
• 7.2. D-Mannose*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Allulose
• 7.4. L-Arabinose
• 7.5. L-Fucose
• 7.6. Others

8. By End-User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.1.2. Market Attractiveness Index, By End-User
• 8.2. Dietary Supplements*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Cosmetics and Personal Care
• 8.4. Pharmaceuticals
• 8.5. Food and Beverage
• 8.6. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. The U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. The U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Russia
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Ingredion Incorporated *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Nestle
• 11.3. Avantor, Inc
• 11.4. Tate & Lyle
• 11.5. Jarrow Formulas Inc
• 11.6. Shijiazhuang Huaxu Pharmaceutical Co.,Ltd
• 11.7. Sanwa Starch Co., Ltd
• 11.8. Zhangjiagang Sipu Biochemical Co., Ltd
• 11.9. Sweet Cures Limited
• 11.10. Matsutani Chemical Industry Co. Ltd

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us